KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Notes Payables (2019 - 2025)

BioNTech SE's Notes Payables history spans 7 years, with the latest figure at $45.0 million for Q3 2025.

  • On a quarterly basis, Notes Payables changed N/A to $45.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $45.0 million, a N/A change, with the full-year FY2023 number at $2.5 million, up 15.5% from a year prior.
  • Notes Payables hit $45.0 million in Q3 2025 for BioNTech SE, up from $44.7 million in the prior quarter.
  • Over the last five years, Notes Payables for BNTX hit a ceiling of $309.3 million in Q2 2021 and a floor of $1.9 million in Q3 2022.
  • Historically, Notes Payables has averaged $89.4 million across 5 years, with a median of $44.7 million in 2025.
  • Biggest five-year swings in Notes Payables: plummeted 98.71% in 2023 and later surged 1844.95% in 2025.
  • Tracing BNTX's Notes Payables over 5 years: stood at $23.1 million in 2021, then crashed by 90.73% to $2.1 million in 2022, then increased by 15.5% to $2.5 million in 2023, then rose by 0.97% to $2.5 million in 2024, then skyrocketed by 1701.33% to $45.0 million in 2025.
  • Business Quant data shows Notes Payables for BNTX at $45.0 million in Q3 2025, $44.7 million in Q2 2025, and $48.6 million in Q1 2025.